Skip to main content
HCWB
NASDAQ Life Sciences

HCW Biologics Restates Q1 EPS Down 37% to $1.39, Cites Unremediated Material Weakness

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.7
Mkt Cap
$4.311M
52W Low
$1.5
52W High
$44.1
52W Position info
80% above low
Off High info
94% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

HCWB sits 80% above its 52-week low of $1.5 on light trading volume (0.1× avg).

Summary

HCW Biologics filed its 10-Q/A restating Q1 2026 EPS from $2.19 to $1.39 due to a warrant accounting error, and disclosed that material weaknesses in internal controls remain unremediated.


Key Events · Earnings and Guidance · HCWB

  • EPS Restated Down 37%

    Q1 2026 basic and diluted EPS restated from $2.19 to $1.39 after applying the two-class method to participating warrants, reducing net income attributable to common stockholders by $728,299.

  • Material Weakness Unremediated

    Management confirms the material weakness in technical accounting review control over complex warrant instruments has not been remediated, and a separate material weakness related to long-lived asset impairment also remains.

  • Going Concern Doubt Persists

    The filing reiterates substantial doubt about the company's ability to continue as a going concern, with cumulative net losses of $102.3 million and negative working capital as of March 31, 2026.

  • Nasdaq Compliance Risk

    The company is awaiting a Nasdaq Hearings Panel determination on its bid price compliance plan, with the stock trading at $2.70 after a 1-for-6 reverse split.


Analysis · HCWB · Life Sciences

The restated Q1 2026 EPS of $1.39 is 37% lower than the previously reported $2.19, driven by the misapplication of the two-class method for participating warrants. The company also confirms that the material weakness in technical accounting review remains unremediated, and a second material weakness related to long-lived asset impairment persists. This raises serious concerns about the reliability of financial reporting for a company already facing going concern doubts and Nasdaq compliance issues.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HCWB was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $1.50 to $44.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HCWB - Latest Insights

HCWB
Nov 05, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $0.8749 info
Change: -$0.2151 (-20%) info
Market Cap: $1.729M info
HCWB
Nov 05, 2026, 8:45 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $0.8749 info
Change: -$0.2851 (-25%) info
Market Cap: $1.729M info
HCWB
Oct 02, 2026, 4:30 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.68
Real-time Price: $0.8749 info
Change: -$0.8051 (-48%) info
Market Cap: $1.729M info
HCWB
Sep 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $0.8749 info
Change: -$0.7751 (-47%) info
Market Cap: $1.729M info
HCWB
Sep 24, 2026, 8:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $0.8749 info
Change: -$0.7251 (-45%) info
Market Cap: $1.729M info